NCT02303353

Brief Summary

The purpose of this registry is to evaluate the situation regarding ambulant therapy of cancer patients in different practices in Germany. It should provide insight into the implementation of schemes for cancer therapy predefined in the guidelines, the treatment of diverse adverse reactions and the counter measures taken. Thereby, potential differences in treatment and with that differences in quality amongst individual practices might be identified. The medium to long term aim is to contribute to positively influence the quality of medical care of cancer patients in Germany.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

November 3, 2014

Completed
24 days until next milestone

First Posted

Study publicly available on registry

November 27, 2014

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2018

Completed
Last Updated

February 24, 2017

Status Verified

February 1, 2017

Enrollment Period

4.9 years

First QC Date

November 3, 2014

Last Update Submit

February 23, 2017

Conditions

Carcinoma

Keywords

Breast cancerOvarian cancerLung cancerColon cancerGastric cancerPancreatic cancerRectum cancerPlasmacytoma

Outcome Measures

Primary Outcomes (1)

  • Anti-cancer treatments (Course of the disease and type of applied anti-cancer therapies. Assessment of guidelines' implementation)

    Course of the disease and type of applied anti-cancer therapies. Assessment of guidelines' implementation

    From date of ICF until date of cure/death/ICF withdrawal, up to 60 months

Secondary Outcomes (1)

  • Adverse reactions and their treatment (Number and type of adverse reactions and applied counter measures / therapies)

    From date of ICF until date of cure/death/ICF withdrawal, up to 60 months

Study Arms (1)

Cancer patients

Patients suffering from a carcinoma (either breast, ovarian, lung, colon, stomach, pancreas, rectum or plasmacytoma)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients suffering from carcinoma which are treated in practices (ambulant therapy)

You may qualify if:

  • years and older
  • Tumor disease (carcinoma of either breast, ovary, lung, colon, stomach, pancreas, rectum or plasmacytoma)
  • Written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Practice

Mannheim, 68165, Germany

RECRUITING

MeSH Terms

Conditions

CarcinomaBreast NeoplasmsOvarian NeoplasmsLung NeoplasmsColonic NeoplasmsStomach NeoplasmsPancreatic NeoplasmsRectal NeoplasmsPlasmacytoma

Condition Hierarchy (Ancestors)

Neoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms by SiteBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesEndocrine Gland NeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal DisordersRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesColorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesStomach DiseasesPancreatic DiseasesRectal DiseasesNeoplasms, Plasma CellLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

Hilde Huber

CONTACT

+49 761 479 400info@akp-freiburg.de

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 3, 2014

First Posted

November 27, 2014

Study Start

October 1, 2013

Primary Completion

September 1, 2018

Study Completion

September 1, 2018

Last Updated

February 24, 2017

Record last verified: 2017-02

Locations

DE(1)